22nd Century Group To Present Its Modified Risk Tobacco Product Application To FDA's Tobacco Products Scientific Advisory Committee

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc.

Benzinga · 12/23/2019 20:40

Meeting is next official step toward possible marketing authorization for 22nd Century Group’s VLN® product in the United States

Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes.

“We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group. “This public meeting is an important milestone for 22nd Century Group and for adult smokers who want to reduce their exposure to nicotine.